Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AURORA-1 oral ASC30 for obesity or overweight with weight-related comorbidities
2026-526172-23-00Phase 3Authorised
- Sponsor
- Ascletis Pharma Inc.
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial in obesity and Overweight comparing ASC30 once daily with Placebo once daily (2 arms). Primary endpoint: Percent change in body weight. Planned start Oct 2026; status: authorised.
02
Drugs
ASC30
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on 2026-526172-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526172-23-00.